Gt Biopharma Stock Alpha and Beta Analysis
| GTBP Stock | USD 2.39 0.06 2.58% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as GT Biopharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in GT Biopharma over a specified time horizon. Remember, high GT Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to GT Biopharma's market risk premium analysis include:
Beta 0.16 | Alpha 0.61 | Risk 9.89 | Sharpe Ratio 0.0386 | Expected Return 0.38 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
GTBP |
GT Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. GT Biopharma market risk premium is the additional return an investor will receive from holding GT Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in GT Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate GT Biopharma's performance over market.| α | 0.61 | β | 0.16 |
GT Biopharma expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of GT Biopharma's Buy-and-hold return. Our buy-and-hold chart shows how GT Biopharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.GT Biopharma Market Price Analysis
Market price analysis indicators help investors to evaluate how GT Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading GT Biopharma shares will generate the highest return on investment. By understating and applying GT Biopharma stock market price indicators, traders can identify GT Biopharma position entry and exit signals to maximize returns.
GT Biopharma Return and Market Media
The median price of GT Biopharma for the period between Sun, Oct 20, 2024 and Sat, Jan 18, 2025 is 2.92 with a coefficient of variation of 13.75. The daily time series for the period is distributed with a sample standard deviation of 0.38, arithmetic mean of 2.78, and mean deviation of 0.31. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 12447 shares by Bristol Investment Fund Ltd of GT Biopharma at 1.25 subject to Rule 16b-3 | 10/25/2024 |
2 | Acquisition by Berk Gregory of 50000 shares of GT Biopharma at 6.33 subject to Rule 16b-3 | 10/31/2024 |
3 | Acquisition by Berk Gregory of 278058 shares of GT Biopharma subject to Rule 16b-3 | 11/13/2024 |
4 | GT Biopharma Reports Third Quarter 2024 Financial Results - GlobeNewswire | 11/14/2024 |
5 | GT Biopharma faces Nasdaq delisting over equity shortfall - Investing.com | 11/27/2024 |
6 | GT Biopharma Stock Rating Upgraded by Roth Capital | 12/03/2024 |
7 | Disposition of 50000 shares by Weldon Steven W of GT Biopharma at 0.28 subject to Rule 16b-3 | 12/17/2024 |
8 | GT Biopharma files for automatic mixed securities shelf | 12/23/2024 |
9 | 12 Health Care Stocks Moving In Mondays Pre-Market Session - Benzinga | 01/13/2025 |
About GT Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including GTBP or other stocks. Alpha measures the amount that position in GT Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Payables Turnover | 0.002371 | 0.002253 | Days Of Inventory On Hand | 61.05 | 86.22 |
GT Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of GT Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, GT Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of GT Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of GT Biopharma. Please utilize our Beneish M Score to check the likelihood of GT Biopharma's management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with GT Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.